Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients.
Marie-Sophie Minot-ThisPascaline Boudou-RouquetteAnne JouinotSixtine de PercinDavid BalakirouchenaneNihel KhoudourCamille TlemsaniJonathan ChauvinAudrey Thomas-SchoemannFrançois GoldwasserBenoit BlanchetJérôme AlexandrePublished in: Pharmaceutics (2022)
≥ 27 mg/L was independently associated with improved 3-month PFS in STS patients. Pharmacokinetically-guided dosing could be helpful to optimize the clinical management of STS patients in daily clinical practice.